Workflow
直写光刻技术
icon
Search documents
研判2025!全球直写光刻设备行业产业链、市场规模、应用领域及未来趋势分析:市场规模恢复增长态势,PCB为最大应用领域[图]
Chan Ye Xin Xi Wang· 2025-09-16 01:12
Core Insights - The direct write lithography market is expected to recover in 2024, with a projected growth of 12% year-on-year, reaching a market size of $1.57 billion due to a significant rebound in downstream industries [1][5][7] - The market is driven by the advantages of direct write lithography technology and its expanding application boundaries, particularly in PCB manufacturing, which is the largest application area [1][7] Industry Overview - Direct write lithography, also known as maskless lithography, utilizes a computer-controlled high-precision beam to project patterns directly onto a substrate coated with photosensitive material without the need for a mask [2][5] - The technology integrates various systems, including graphic processing, high-precision displacement platforms, optical systems, and control systems, making it a key device in micro-nano manufacturing [2][5] Market Dynamics - The global direct write lithography equipment market has shown volatility in recent years due to a slowdown in economic growth and pressure on downstream industries [5][6] - The PCB sector is the largest application area for direct write lithography, accounting for 41.1% of the market in 2024, followed by the mask plate sector at 36.6% [7][8] Competitive Landscape - Major players in the PCB direct imaging equipment sector include Israel's Orbotech, Japan's ORC, ADTEC, SCREEN, and domestic companies such as Chipbond and Jiangsu Yingsu [1][5][6] - In the broader semiconductor direct write lithography market, foreign companies dominate, with competitors including Sweden's Mycronic, Germany's Heidelberg, and Japan's SCREEN [1][5][6] Technological Trends - The direct write lithography technology is evolving to achieve finer line widths and higher resolution, driven by the increasing integration and performance demands of downstream electronic products [14][16] - The industry is focusing on improving production yield and balancing the cost of equipment upgrades with production efficiency [17][18] Application Insights - The PCB manufacturing process is complex and requires various specialized equipment, with direct imaging technology becoming the mainstream method due to its advantages over traditional exposure techniques [8][9] - The global PCB market is projected to reach $73.6 billion in 2024, with a growth rate of 5.8%, driven by demand from AI servers and data center equipment [7][8] Future Outlook - The demand for direct write lithography equipment in advanced packaging is expected to grow significantly, with a projected market size of $30 million by 2030 as the technology matures [13][14]
芯碁微装冲击A+H,专注于光刻设备领域,应收账款压力较大
Ge Long Hui· 2025-09-05 09:52
Core Viewpoint - The news highlights the significant performance of the A-share market, particularly the rebound of the ChiNext Index after a notable drop, and the impressive stock performance of Shenghong Technology, which has seen a year-to-date increase of over 600% [1][2]. Company Overview - Chip Microelectronics Equipment Co., Ltd. (芯碁微装) is seeking to list on the Hong Kong Stock Exchange, having submitted its prospectus on August 31, with CICC as the sponsor [2]. - The company was listed on the STAR Market in April 2021, with a current market capitalization of approximately 18.2 billion RMB [3]. Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the first half of 2025 was reported as 652 million RMB, 829 million RMB, 954 million RMB, and 654 million RMB respectively, indicating a compound annual growth rate (CAGR) of 20.9% from 2022 to 2024 [16]. - Net profits for the same periods were 137 million RMB, 179 million RMB, 161 million RMB, and 142 million RMB, showing fluctuations [16]. - The gross profit margins for the company were 41.3%, 40.9%, 35.5%, and 40.5% during the reporting periods, with a noted decline in 2024 due to a higher proportion of lower-margin PCB products [20]. Product and Market Position - Chip Microelectronics focuses on micro-nano direct imaging lithography technology, producing direct imaging equipment and supporting services for PCB and semiconductor manufacturing [8][11]. - The company holds a 15% market share in the global PCB direct imaging equipment sector, making it the largest supplier in this market [27][34]. - The global market for PCB direct imaging equipment is projected to grow from approximately 4.6 billion RMB in 2024 to 6.7 billion RMB by 2030, with a CAGR of 6.6% [33]. Customer Base and Industry Dynamics - The company has supplied over 600 clients, including major PCB manufacturers and advanced packaging clients in the semiconductor sector [23][24]. - The demand for high-end PCBs has surged due to the growth of the AI industry, contributing to the company's revenue growth [16]. Challenges - The company faces challenges with high accounts receivable, with net accounts receivable amounting to 584 million RMB, 850 million RMB, 1.017 billion RMB, and 1.122 billion RMB, representing 89.57%, 102.53%, 106.60%, and 171.56% of total revenue respectively [24]. - Operating cash flows have been negative in recent years, indicating financial pressure [25].
芯碁微装(688630):领先的LDI设备公司,受益PCB设备投资扩张与先进封装产业趋势
KAIYUAN SECURITIES· 2025-07-29 09:05
Investment Rating - The investment rating for the company is "Buy" [9] Core Views - The company benefits from the expansion of PCB equipment and the acceleration of semiconductor equipment layout, maintaining a "Buy" rating. Despite a downward revision of the company's annual profit forecast due to limited capacity in the first phase of the factory, the company is expected to benefit from downstream PCB manufacturers' expansion and the upcoming production of the second-phase factory, leading to a positive mid-term performance release. Long-term, the company's semiconductor business is gradually constructing multiple growth drivers, with projected revenues of 1.5 billion, 2.2 billion, and 2.7 billion yuan for 2025, 2026, and 2027 respectively, and net profits of 300 million, 516 million, and 709 million yuan for the same years [5][6][9]. Company Overview - The company is a leading manufacturer of direct imaging lithography equipment, primarily serving the PCB and semiconductor sectors. Its products include direct imaging equipment for PCB and semiconductor applications, covering various processes from microns to nanometers. The company has a complete range of LDI equipment for PCB manufacturing, including IC substrates, HDI, and flexible printed circuits [6][15]. PCB Business - The PCB business is driven by high-end demand from AI infrastructure, with optimistic capital expenditure guidance from PCB manufacturers. The company has maintained a full order book since Q2 2024, but growth has been limited by capacity constraints. The gradual production of the second-phase factory is expected to release capacity and positively impact order growth [6][15]. Semiconductor Business - The semiconductor business is accelerating its industrialization process, with multiple layouts constructing a new growth curve. The company is focusing on advanced packaging technologies and has successfully completed product validation for several advanced packaging customers. The company is also making steady progress in the general semiconductor field, benefiting from the long-term trend of domestic substitution [7][36]. Financial Summary and Valuation Metrics - The company's revenue has shown steady growth, with a projected revenue of 1.467 billion yuan in 2025, representing a year-on-year increase of 53.8%. The net profit is expected to reach 300 million yuan, with a year-on-year growth of 86.7%. The gross margin is projected to be 39.9% in 2025, with a net margin of 20.4% [8][34]. Market Position - The company has established a strong market position with a complete range of products covering various PCB types and processes. It has successfully penetrated the high-end PCB market and is positioned to benefit from the ongoing expansion in the semiconductor sector [6][15].
【私募调研记录】彤源投资调研上海家化、卓易信息等4只个股(附名单)
Zheng Quan Zhi Xing· 2025-04-29 00:10
Group 1: Shanghai Jahwa - Shanghai Jahwa is confident about achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The employee stock ownership plan aims to enhance competitiveness, reduce turnover, and foster a sense of ownership among employees [1] - The company has made strategic adjustments in the past six months, including organizational design, talent development, and cultural initiatives [1] - E-commerce strategies include inventory optimization, pricing adjustments, organizational restructuring, and product iteration [1] - The company targets double-digit revenue growth this year and aims to turn profits around [1] - Long-term profit recovery is expected to follow a 1-2 year revenue growth, 2-3 year profit improvement, and 3-5 year profit margin targets [1] Group 2: Zhuoyi Information - Zhuoyi Information has approximately 7,000 active users for its SnapDevelop platform and plans to release a paid commercial version [2] - EazyDevelop, which focuses on rapid development using AI technology, will have a free trial version available after development [2] - The company has made breakthroughs in RISC-V firmware and is collaborating with major firms like Huawei and Lenovo [2] Group 3: Chipbond Technology - Chipbond Technology has made progress in advanced packaging, with its WLP2000 equipment entering mass production preparation after client validation [3] - The company benefits from advantageous direct-write lithography technology and has seen a 22.31% year-on-year increase in revenue and a 30.45% increase in net profit in Q1 [3] - The company expects overseas orders to account for nearly 20% by 2024, indicating strong international market competitiveness [3] Group 4: Kanghong Pharmaceutical - Kanghong Pharmaceutical's KPB-101 has established a leading position in China's ophthalmic anti-VEGF market and aims for further achievements [4] - The company focuses on diverse research and development in ophthalmology, neurology, and oncology, with a strong emphasis on innovative drug sales [4] - The company anticipates a revenue and net profit growth of 5%-15% year-on-year by 2025, with specific products expected to see significant sales growth [4]